From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. General Medicine>
  4. Summary and Comment

Is Enoxaparin Safe for Patients with Renal Failure?

Enoxaparin's manufacturer now recommends specific reduced doses for patients with creatinine clearance <30 mL/minute.

Unlike unfractionated heparin (UFH), the low-molecular-weight heparin enoxaparin (Lovenox) is excreted mainly by the kidneys. To determine whether this characteristic heightens bleeding risk in patients with renal insufficiency, researchers in Connecticut compared bleeding rates with enoxaparin and UFH in a retrospective study of 620 hospitalized patients with renal insufficiency.

All patients received full therapeutic doses of enoxaparin or UFH. Renal insufficiency was mild (glomerular filtration rate, 41-60 mL/minute) in 50%, moderate (21-40 mL/minute) in 34%, and severe (≤20 mL/minute) in 16%. In analyses that were adjusted for potential confounders, rates of major bleeding did not differ significantly between enoxaparin and UFH recipients, regardless of the degree of renal impairment. However, minor bleeding was significantly more common with enoxaparin than with UFH in the subgroup with severe impairment (rate, 68 vs. 27 minor bleeds per 1000 person-days). Overall, 10% of patients had major bleeding, and 14% had minor bleeding.

Comment: In this nonrandomized, retrospective study, minor (but not major) bleeding was significantly more common with enoxaparin than with UFH among patients with severe renal insufficiency. In December 2003, the official prescribing information for enoxaparin changed to reflect data from new manufacturer-sponsored research on enoxaparin pharmacokinetics. For patients with creatinine clearance <30 mL/minute, the new prescribing information recommends reduced doses of 30 mg once daily for DVT prophylaxis and 1 mg/kg once daily for treatment of venous thromboembolism, unstable angina, and non-Q-wave myocardial infarction. Standard doses still are recommended for patients with milder degrees of renal impairment.

— Allan S. Brett, MD

Published in Journal Watch General Medicine April 20, 2004

Citation(s):

Thorevska N et al. Anticoagulation in hospitalized patients with renal insufficiency: A comparison of bleeding rates with unfractionated heparin vs enoxaparin. Chest 2004 Mar; 125:856-63.

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. Please consider this when composing your remark.

Fields marked with an * are required.

Name as you'd like it to appear:

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

 

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Advanced

Article Tools

Reader Remarks

Sign-In

Forgot your password?

New to Journal Watch?

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Journal Watch Newsletters

Available in 13 specialties with convenient delivery and 10 free online CME exams.

Subscribe Now!

Copyright © 2004. Massachusetts Medical Society. All rights reserved.